Loading…
Contineum Therapeutics, Inc. is projected to rise to $17.50 by 2027, a +13% move from its current price of $15.49. CTNM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $14.95 | $15.49 | $16.04 | -0.02% |
| Aug 3 | $14.74 | $15.48 | $16.27 | -0.05% |
| Aug 4 | $14.57 | $15.48 | $16.44 | -0.07% |
| Aug 5 | $14.43 | $15.47 | $16.59 | -0.10% |
| Aug 6 | $14.31 | $15.47 | $16.73 | -0.12% |
| Aug 7 | $14.20 | $15.47 | $16.85 | -0.15% |
| Aug 8 | $14.10 | $15.46 | $16.96 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.10 | $15.46 | $16.96 | -0.17% |
| Week 2 | $13.54 | $15.44 | $17.59 | -0.35% |
| Week 3 | $13.13 | $15.41 | $18.09 | -0.52% |
| Week 4 | $12.79 | $15.38 | $18.51 | -0.69% |
| Week 5 | $12.49 | $15.36 | $18.88 | -0.86% |
| Week 6 | $12.22 | $15.33 | $19.23 | -1.03% |
| Week 7 | $11.98 | $15.30 | $19.54 | -1.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Contineum Therapeutics, Inc., CTNM, is a clinical stage biopharmaceutical company focused on developing small molecule therapies for neuroscience, inflammation, and immunology indications in the United States.
The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Contineum Therapeutics, Inc. (CTNM) is a healthcare company with a current price of $15.75. It sits in the Healthcare category and has a market capitalization of $588.84M, with a market rank of 2729.
Forecast-wise, the near-term view is mixed: the 2026 average price is $15.75 with neutral sentiment, while longer horizons show a path toward higher prices. The 2030 average price is $25.42, and the 2040 average is $61.00, rising further to a 2050 average of $130.05, indicating substantial longer-term upside despite earlier modest movements.
A major floor 37.2% below — a decisive break under it would weaken the trend.
The nearest floor, 25.0% below — buyers have tended to step in here.
The nearest ceiling, 5.8% above — a clean break opens room to run.
A major ceiling 24.4% above — clearing it would confirm fresh momentum.
Key CTNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.73 | Buy | $14.98 | Buy |
| MA 10 | $14.42 | Buy | $14.70 | Buy |
| MA 20 | $14.63 | Buy | $14.47 | Buy |
| MA 50 | $13.66 | Buy | $13.99 | Buy |
| MA 100 | $13.45 | Buy | $13.57 | Buy |
| MA 200 | $12.90 | Buy | $12.77 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.30 | Neutral |
| Stoch RSI (14) | 85.01 | Sell |
| CCI (20) | 106.62 | Buy |
| Williams %R (14) | -11.71 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 5.88 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 88.29 | Sell |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 0.63 | Buy |
| Ultimate (7,14,28) | 61.10 | Neutral |
| Momentum (10) | 1.26 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 15.27 | Buy |
| ADX (14) | 11.95 | Neutral |
| ATR (14) | 0.48 | Info |
The 30-day technical picture is bullish, reflecting positive near-term momentum. RSI14 is 60, with the 50-day simple moving average at $13.60 and the 200-day simple moving average at $12.88.
The security trades within a 30-day range of $12.43 to $19.95, signaling that recent price action has oscillated above and below the current price. Support is reported at $11.62 and resistance at $16.39, framing potential entry and exit points in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.17 | $15.49 | $18.50 | 0% | Neutral | |
| $13.60 | $17.50 | $24.01 | +13% | Neutral | |
| $13.10 | $17.49 | $25.13 | +13% | Neutral | |
| $13.14 | $18.10 | $26.95 | +17% | Neutral | |
| $17.13 | $24.25 | $37.21 | +57% | Bullish | |
| $19.59 | $28.45 | $44.80 | +84% | Bullish | |
| $21.43 | $31.86 | $51.34 | +106% | Bullish | |
| $21.97 | $33.40 | $54.95 | +116% | Bullish | |
| $20.33 | $31.57 | $52.93 | +104% | Bullish | |
| $22.39 | $35.48 | $60.55 | +129% | Bullish | |
| $32.84 | $57.21 | $105.04 | +269% | Bullish | |
| $58.13 | $119.86 | $244.51 | +674% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.17 | $15.49 | $18.09 | +0.00% |
| September 2026 | $12.60 | $15.03 | $18.53 | -2.95% |
| October 2026 | $12.58 | $15.14 | $18.92 | +0.74% |
| November 2026 | $12.05 | $14.61 | $18.45 | -3.53% |
| December 2026 | $11.89 | $14.51 | $18.50 | -0.69% |
Click any year to see its month-by-month CTNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Contineum Therapeutics, Inc.'s 2026 outlook centres on $15.49, within a $9.17 to $18.50 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CTNM could reach as high as $24.01, with a base case around $17.50 and support toward $13.60 — roughly +13% from $15.49. Price action looks broadly range-bound.
Expect CTNM to range from $13.10 to $25.13 through 2028. The $17.49 average target implies a +13% move from current prices. That is 0% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The CTNM price prediction for 2029 points to an average of $18.10 (low $13.14, high $26.95) — a potential gain of +17% on today's $15.49. Price action looks broadly range-bound.
In 2030, CTNM is projected to trade between $17.13 and $37.21, averaging $24.25 — a potential gain of +57% from today's $15.49. That is up +34% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Contineum Therapeutics, Inc.'s 2031 outlook centres on $28.45, within a $19.59 to $44.80 range. That is up +17% on the projected 2030 average. That marks a +84% change versus current levels. Momentum favours further upside here.
By 2032, CTNM could reach as high as $51.34, with a base case around $31.86 and support toward $21.43 — roughly +106% from $15.49. Buyers look set to stay in control over this stretch.
Expect CTNM to range from $21.97 to $54.95 through 2033. The $33.40 average target implies a +116% move from current prices. That is up +5% on the projected 2032 average. Momentum favours further upside here.
The CTNM price prediction for 2034 points to an average of $31.57 (low $20.33, high $52.93) — a potential gain of +104% on today's $15.49. Buyers look set to stay in control over this stretch.
In 2035, CTNM is projected to trade between $22.39 and $60.55, averaging $35.48 — a potential gain of +129% from today's $15.49. That is up +12% on the projected 2034 average. Momentum favours further upside here.
Contineum Therapeutics, Inc.'s 2040 outlook centres on $57.21, within a $32.84 to $105.04 range. That is up +61% on the projected 2035 average. That marks a +269% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CTNM could reach as high as $244.51, with a base case around $119.86 and support toward $58.13 — roughly +674% from $15.49. Momentum favours further upside here.
Investing $1,000 in CTNM today (≈ 64.557779 CTNM) could be worth
$7,737.8
+$6,737.8 (+674%) by 2050 · US Dollar
Based on the average projected CTNM price of $119.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTNMwould be worth at today's price.
$1,000 invested in CTNM on Jul 31, 2025 (≈ 169.491523 CTNM) would be worth
$2,625.42
+$1,625.42 (+162.5%) today · 2.63× · US Dollar
Based on a CTNM entry price of $5.9 vs. today's $15.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.06 | $1,101.71 | +10.2% |
| 1 month ago | $15.24 | $1,016.4 | +1.6% |
| 3 months ago | $13.2 | $1,173.48 | +17.3% |
| 6 months ago | $14.38 | $1,077.19 | +7.7% |
| 1 year ago | $5.9 | $2,625.42 | +162.5% |
| All time (2.3y) ago | $15.4 | $1,005.84 | +0.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTNM forecast.
Our base-case forecast reaches $31.00 around 2032.
Implied market cap at $31.00: $1.02B
The multi-year forecast shows a stepwise path to higher levels beginning in 2030. For 2026 the min is $9.17, the avg $15.75, the max $18.87, with ROI of 0% and neutral sentiment. In 2027 and 2028 the avg is $17.94 (min $13.90, max $24.72) with ROI of 13.9% and neutral sentiment, followed by 2029 with avg $18.69 (min $13.49, max $28.00) and ROI of 18.7%.
From 2030 onward, the forecast turns bullish. 2030 shows avg $25.42 (min $17.84, max $39.26) and ROI 61.4%. 2031, 2032, 2033, 2034, and 2035 continue the bullish arc with avg values of $29.83, $33.50, $35.17, $33.15, and $37.56 respectively, and ROI figures of 89.4%, 112.7%, 123.3%, 110.5%, and 138.5%.
The momentum continues to accelerate into 2040 and 2050, with 2040 avg $61.00 (min $34.53, max $113.13) and ROI 287.3%, and 2050 avg $130.05 (min $61.72, max $268.40) and ROI 725.7%. Both years carry a bullish sentiment.
These figures are estimates and not guarantees; actual results may differ due to factors affecting the clinical and commercial landscape.
Tap a question to reveal the answer.
2030 avg price $25.42; min $17.84; max $39.26; ROI 61.4%; sentiment BULLISH.
Forecasts show neutral sentiment in 2026–2029, then bullish momentum from 2030 onward, with 2030 avg $25.42 and higher in 2040 ($61.00) and 2050 ($130.05). ROI progresses from 0% in 2026 to 61.4% (2030), 287.3% (2040), and 725.7% (2050). These are estimates, not guarantees.
No. The 2040 max price is $113.13, while the 2050 max is $268.40, so $150 is not reached by 2040 according to the forecast.
Current price is $15.75 and market cap is $588.84M.
2040: avg $61.00; min $34.53; max $113.13; ROI 287.3%; sentiment BULLISH. 2050: avg $130.05; min $61.72; max $268.40; ROI 725.7%; sentiment BULLISH.
Contineum Therapeutics, Inc. Community Discussion
0Share your Contineum Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.